Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
Sign-on Letter Opposing the Patent Eligibility Restoraction Act of 2024
-
ACMG Reseponse to Alabama Supreme Court Decision on Embryos
-
ACMG Comments on FDA Proposed Rule for Regulation of LDTs
-
Stakeholder Letter Asking Congress Renew Efforts on CLIA Reform and Urge FDA to Halt LDT Rulemaking
-
Letter to FDA Requesting Extension of Comment Period for Proposed Rule on Regulation of LDTs
-
ACMG Request to FDA to Extend Comment Period for Proposed Rule on Regulation of LDTs
-
Sign-on Letter Opposing Updated VALID Act & ACM Exemption
-
Sign-on Letter to Congressional Leadership Concerning the VALID Act
-
ACMG Comments on FDA Draft Guidance for Products Incorporating Genome Editing
-
ACMG Response to Opposing Inclusion of the VALID Act in the FDASLA Act